TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28567555

Group type: EXPERIMENTAL
Intervention: e‐PROMs questionnaire (completed online on a monthly basis for 12 months)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (continued care in the same style for 12 months)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: e‐PROMs questionnaire
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Number of flares (regardless of severity)
Number of subjects: 147
Study: 26043004

Group type: EXPERIMENTAL
Intervention: Aspheric IOL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spherical IOL
Number of subjects: 40
Study: 22994457

Group type: EXPERIMENTAL
Intervention: QuitCoach personalized tailored internet‐delivered advice program
Number of subjects: 3530

Group type: EXPERIMENTAL
Intervention: onQ, an interactive automated text‐messaging program
Number of subjects: 3530

Group type: EXPERIMENTAL
Intervention: Integration of both QuitCoach and onQ
Number of subjects: 3530

Group type: EXPERIMENTAL
Intervention: Choice of either alone or the combined program
Number of subjects: 3530

Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 3530

Group type: EXPERIMENTAL
Intervention: Intervention users
Number of subjects: 3530
Study: 21657119

Group type: EXPERIMENTAL
Intervention: Assertive Outreach (AO)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 83
Study: 19842940

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of coumarin derivatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dosing of coumarin derivatives (control group not explicitly mentioned)
Number of subjects: 0
Study: 16751015

Group type: EXPERIMENTAL
Intervention: 50 microg of Qbeta-Der p 1 intramuscularly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 microg of Qbeta-Der p 1 subcutaneously
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 microg of Qbeta-Der p 1 intramuscularly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 microg of Qbeta-Der p 1 subcutaneously
Number of subjects: 24
Study: 14501305

Group type: EXPERIMENTAL
Intervention: Long-term exercise program (50-70 minutes, 5 days per week, including aerobic activity, resistance training, and dynamic exercise)
Number of subjects: 0
Study: 10972632

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg once daily for 4 weeks, then titrated to 160 mg once daily for an additional 4 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 146

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 146
Study: 8829024

Group type: EXPERIMENTAL
Intervention: Ticlopidine hydrochloride 200 mg once daily and nicardipine hydrochloride 20 mg three times daily (TID)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ticlopidine hydrochloride 200 mg once daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg once daily and nicardipine hydrochloride 20 mg TID
Number of subjects: 57

Group type: COMPARATOR
Intervention: Aspirin 81 mg once daily
Number of subjects: 57
Study: 1578042

Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD) with HI-LO Evac tube
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 145

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 145
Study: 2865028

Group type: EXPERIMENTAL
Intervention: 10 mg betaxolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 40 mg betaxolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29625020

Group type: EXPERIMENTAL
Intervention: Temporal artery thermometry
Number of subjects: 68

Group type: COMPARATOR
Intervention: Axillary thermometry
Number of subjects: 68
Study: 27495093

Group type: EXPERIMENTAL
Intervention: Rescuefix
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tape (Durapore)
Number of subjects: 44
Study: 24093552

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamins A, B-complex, C, E, and selenium)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 423
Study: 23149503

Group type: EXPERIMENTAL
Intervention: Narrow body implants (NBIs) with 2.2‐ or 2.4‐mm diameter
Number of subjects: 10
Study: 20638454

Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (10 or 15 microg) in children aged 3-11 years
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (30 microg) in children aged 12-17 years
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated whole-virion vaccine (5 microg) in children aged 12-17 years
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (5-30 microg) in children aged 12-17 years
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (5-15 microg) in children aged 3-11 years
Number of subjects: 421
Study: 18339115

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 200 mg daily in divided doses)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15814029

Group type: EXPERIMENTAL
Intervention: Mefloquine alone (25 mg/kg single dose)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Artesunate followed by mefloquine (4 mg/kg/day for 3 days followed by 15 mg/kg on day 3)
Number of subjects: 78
Study: 12414332

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 mg or 100 mg)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 mg or 100 mg) and Placebo
Number of subjects: 443
Study: 12580211

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 50
Study: 8639079

Group type: EXPERIMENTAL
Intervention: Direct laser photocoagulation
Number of subjects: 38

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CSR eyes
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonaffected fellow eyes
Number of subjects: 38
Study: 1612530

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (SCT) 100 IU daily plus calcium 500 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (SCT) 100 IU daily for alternate cycles of 2 months with a 1‐month interval plus calcium 500 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (SCT) 100 IU daily for alternate cycles of 3 months of treatment followed by a 3‐month interval plus calcium 500 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium 500 mg daily alone (control group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proximal and distal forearm bone density (treated and control groups)
Number of subjects: 60
Study: 6423316

Group type: EXPERIMENTAL
Intervention: Oral disodium cromoglycate (DSCG) at a dose of 100 mg/kg/day in four divided doses for 6 months
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 30001288

Group type: EXPERIMENTAL
Intervention: Colonoscopic enema of 1 L polyethylene glycol (PEG)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Additional oral intake of 2 L polyethylene glycol (PEG)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Colonoscopic enema of 1 L PEG
Number of subjects: 131
Study: 30317015

Group type: EXPERIMENTAL
Intervention: Home-based exercise programmes
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Self-initiated training strategy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Individually supervised physiotherapy treatment
Number of subjects: 44
Study: 27457916

Group type: EXPERIMENTAL
Intervention: Contract-relax stretching
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 24388920

Group type: EXPERIMENTAL
Intervention: Polyphenon E (800 mg epigallocatechin gallate)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Polyphenon E
Number of subjects: 98
Study: 22248928

Group type: EXPERIMENTAL
Intervention: Cold pressor stress test
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stress-induced cortisol
Number of subjects: 80
Study: 20036378

Group type: EXPERIMENTAL
Intervention: Exclusively human milk-based diet
Number of subjects: 207

Group type: COMPARATOR
Intervention: Human milk and bovine milk-based products diet
Number of subjects: 207
Study: 17033900

Group type: EXPERIMENTAL
Intervention: 75,000 SQ-T grass allergen tablets
Number of subjects: 855

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 855

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 855
Study: 15652877

Group type: EXPERIMENTAL
Intervention: BPD subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 11582601

Group type: EXPERIMENTAL
Intervention: Awareness of HAART
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Belief that those taking HAART are 'no longer' or 'less' infective
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Belief that persons taking HAART are less infective
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Not aware of HAART
Number of subjects: 4000
Study: 9289913

Group type: EXPERIMENTAL
Intervention: Polyvitamin pills 'Duovit'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premix 'Roche'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supplement of third dishes with vitamin C
Number of subjects: 0
Study: 8501579

Group type: EXPERIMENTAL
Intervention: Didanosine 120 mg/m2 per day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Didanosine 270 mg/m2 per day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 2892517

Group type: EXPERIMENTAL
Intervention: Sufentanil 5 micrograms/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 40
Study: 2783184

Group type: EXPERIMENTAL
Intervention: Mexiprostil 800 micrograms (tablet and capsule)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mexiprostil 1200 micrograms (tablet and capsule)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mexiprostil (both doses and formulations)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4909818

Group type: EXPERIMENTAL
Intervention: Duogastrone capsules, one four times daily, half-an-hour before meals
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo containing magnesium trisilicate
Number of subjects: 14
Study: 31958337

Group type: EXPERIMENTAL
Intervention: Letrozole (Lz) 2.5 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Testosterone (T) 1 mg/kg/month
Number of subjects: 28
Study: 29761352

Group type: EXPERIMENTAL
Intervention: Virtual-reality simulator test for robotic surgical skills
Number of subjects: 32
Study: 27922950

Group type: EXPERIMENTAL
Intervention: CIESI with targeted epidural catheter
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard C7-T1 CIESI
Number of subjects: 76
Study: 25727522

Group type: EXPERIMENTAL
Intervention: Lifestyle counselling intervention (diet, smoking cessation, and exercise)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Lifestyle counselling intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Regular instructions (control group)
Number of subjects: 500
Study: 23187726

Group type: EXPERIMENTAL
Intervention: Placebo administration
Number of subjects: 50
Study: 21996393

Group type: EXPERIMENTAL
Intervention: Lenient rate control (resting HR <110 beats/min)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Strict rate control (resting HR <80 beats/min, HR during moderate exercise <110 beats/min)
Number of subjects: 614
Study: 19679277

Group type: EXPERIMENTAL
Intervention: Treatment targeting increased neuronal hyperexcitability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 17039215

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB) plus standard rehabilitation treatment (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard rehabilitation treatment alone (Group B)
Number of subjects: 40
Study: 14676787

Group type: EXPERIMENTAL
Intervention: High-dose intravenous melphalan and autologous stem cell transplantation (HDM/SCT) as initial therapy (Arm-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-dose intravenous melphalan and autologous stem cell transplantation (HDM/SCT) following two cycles of oral melphalan and prednisone (Arm-2)
Number of subjects: 100
Study: 11303137

Group type: EXPERIMENTAL
Intervention: Enteral fluconazole 400 mg per day
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 9283994

Group type: EXPERIMENTAL
Intervention: Colloidal silicic acid gel, orally and topically, 30 ml daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel, orally and topically, identical treatment as the intervention group
Number of subjects: 30
Study: 7687592

Group type: EXPERIMENTAL
Intervention: Active medication 1
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Active medication 2
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 3752487

Group type: EXPERIMENTAL
Intervention: Thiopentone (3 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiopentone (6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methohexitone (1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methohexitone (2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 0
Study: 29336718

Group type: EXPERIMENTAL
Intervention: Irvingia gabonensis (150 mg) twice a day for 90 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27679518

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patiromer (dosing regimen study)
Number of subjects: 0
Study: 25031328

Group type: EXPERIMENTAL
Intervention: Iron-improved amaranth sauce
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Iron-improved jute sauce
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional amaranth sauce
Number of subjects: 18
Study: 22375895

Group type: EXPERIMENTAL
Intervention: Lay Pregnancy Outreach Worker (POW) service
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 1316
Study: 20331895

Group type: EXPERIMENTAL
Intervention: Rapid antigen detection testing (RADT) for GABHS in acute pharyngitis
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (no RADT)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Intervention group (RADT)
Number of subjects: 276
Study: 17971713

Group type: EXPERIMENTAL
Intervention: ATV300/RTV (Atazanavir 300 mg with Ritonavir 100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATV400 (Atazanavir 400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ATV300/RTV
Number of subjects: 0

Group type: COMPARATOR
Intervention: ATV400
Number of subjects: 0
Study: 17180590

Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 12834498

Group type: EXPERIMENTAL
Intervention: GRA10
Number of subjects: 39

Group type: COMPARATOR
Intervention: GRA1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PP10
Number of subjects: 39

Group type: COMPARATOR
Intervention: PP1
Number of subjects: 39
Study: 10790931

Group type: EXPERIMENTAL
Intervention: Nutritional assessment and counselling of mothers and carers, introduction of the Strong Women, Strong Babies, Strong Culture program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-intervention conditions
Number of subjects: 0
Study: 9309287

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 16
Study: 8296384

Group type: EXPERIMENTAL
Intervention: High-titre Edmonston-Zagreb (EZ) measles vaccine administered at 5 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-titre Schwarz (SW-HT) measles vaccine administered at 5 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard Schwarz (SW-std) measles vaccine administered at 10 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered at 5 months
Number of subjects: 0
Study: 3443142

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily with omeprazole 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol 80 mg twice daily with placebo
Number of subjects: 8
Study: 31658396

Group type: EXPERIMENTAL
Intervention: HL2351 (1, 2, 4, 8 and 12 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anakinra (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30415859

Group type: EXPERIMENTAL
Intervention: W0 (drinking water offered from birth)
Number of subjects: 30

Group type: COMPARATOR
Intervention: W17 (drinking water offered at 17 d of age)
Number of subjects: 30
Study: 27891663

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25686055

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (Group A) - pycnogenol 50 mg, Vitamin E 30 mg, coenzyme Q10 20 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Untreated control group (Group B)
Number of subjects: 68
Study: 22251879

Group type: EXPERIMENTAL
Intervention: Immediate implant treatment (IIT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional implant treatment (CIT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Grafted implant treatment (GIT)
Number of subjects: 48
Study: 21527519

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 18463848

Group type: EXPERIMENTAL
Intervention: Standard care plus extracorporeal therapy with PMX-B
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 16
Study: 16243418

Group type: EXPERIMENTAL
Intervention: Cyamemazine (25-50 mg q.d.)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Bromazepam (3-6 mg q.d.)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cyamemazine
Number of subjects: 168

Group type: COMPARATOR
Intervention: Bromazepam
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cyamemazine and Bromazepam
Number of subjects: 168
Study: 12795087

Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed
Number of subjects: 456

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 456
Study: 11103484

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Morphine-bupivacaine combination
Number of subjects: 45
Study: 8925577

Group type: EXPERIMENTAL
Intervention: Diabetic group (n=77)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Nondiabetic group (n=481)
Number of subjects: 558
Study: 1642185

Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine
Number of subjects: 39
Study: 6463180

Group type: EXPERIMENTAL
Intervention: 65 dB SPL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80 dB SPL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 95 dB SPL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 110 dB SPL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simple reaction time task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Passive sitting task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Visual tracking task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SCR amplitude
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: P300 and other event‐related potentials
Number of subjects: 12
Study: 31299751

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein (BMP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no BMP or PRF)
Number of subjects: 32
Study: 29438271

Group type: EXPERIMENTAL
Intervention: 200 μg of misoprostol
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 25801339

Group type: EXPERIMENTAL
Intervention: Immediate loading of implants (test group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unloaded implants for 3 months (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implants with TiUnite surface (AOX)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implants with machine-milled surface (AM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implants at implant level (IL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall implant survival rate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Soft tissue response
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Probing pocket depths
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bleeding on probing (BoP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Soft tissue retraction
Number of subjects: 50
Study: 24669986

Group type: EXPERIMENTAL
Intervention: DHA-enriched almond-based beverage
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (almond-based beverage)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Training season
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 15
Study: 22343483

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Moderate-dose MPH
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-dose MPH
Number of subjects: 34
Study: 20509332

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (Vitamin E) 200 mg/day for 21 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17719507

Group type: EXPERIMENTAL
Intervention: START triage protocol (scoring based on respiratory rate, pulse, and Glasgow Coma Scale)
Number of subjects: 355